If you have been reading about gastric juice protein and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
| Property | Value | Notes |
|---|---|---|
| Typical storage | Minus 20 C or below | Lyophilized powder, protected from light |
| Solubility class | Freely soluble in water | Also dissolves in normal saline |
| Identity method | Mass spectrometry | Measured mass compared with calculated value |
| Purity method | Reverse-phase HPLC | Reported as area percentage of main peak |
| Common counterion | Acetate | Salt form varies by supplier and batch |
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Agouti-signaling protein is a protein that in humans is encoded by the ASIP gene. It is responsible for the distribution of melanin pigment in mammals. Agouti interacts with the melanocortin 1 receptor to determine whether the melanocyte (pigment cell) produces phaeomelanin (a red to yellow pigment), or eumelanin (a brown to black pigment). This interaction is responsible for making distinct light and dark bands in the hairs of animals such as the agouti, which the gene is named after. In other species such as horses, agouti signalling is responsible for determining which parts of the body will be red or black. Mice with wildtype agouti will be grey-brown, with each hair being partly yellow and partly black. Loss of function mutations in mice and other species cause black fur coloration, while mutations causing expression throughout the whole body in mice cause yellow fur and obesity. The agouti-signaling protein (ASIP) is a competitive antagonist with alpha-Melanocyte-stimulating hormone (α-MSH) to bind with melanocortin 1 receptor (MC1R) proteins. Activation by α-MSH causes production of the darker eumelanin, while activation by ASIP causes production of the redder phaeomelanin. This means where and while agouti is being expressed, the part of the hair that is growing will come out yellow rather than black.
RNA splicing is the process by which introns, regions of RNA that do not code for proteins, are removed from the pre-mRNA and the remaining exons connected to re-form a single continuous molecule. Exons are sections of mRNA which become "expressed" or translated into a protein. They are the coding portions of a mRNA molecule. Although most RNA splicing occurs after the complete synthesis and end-capping of the pre-mRNA, transcripts with many exons can be spliced co-transcriptionally. The splicing reaction is catalyzed by a large protein complex called the spliceosome assembled from proteins and small nuclear RNA molecules that recognize splice sites in the pre-mRNA sequence. Many pre-mRNAs, including those encoding antibodies, can be spliced in multiple ways to produce different mature mRNAs that encode different protein sequences. This process is known as alternative splicing, and allows production of a large variety of proteins from a limited amount of DNA.
The first genetically modified animal to be commercialized was the GloFish (2003) and the first genetically modified animal to be approved for food use was the AquAdvantage salmon in 2015. Bacteria are the easiest organisms to engineer and have been used for research, food production, industrial protein purification (including drugs), agriculture, and art. There is potential to use them for environmental purposes or as medicine. Fungi have been engineered with much the same goals. Viruses play an important role as vectors for inserting genetic information into other organisms. This use is especially relevant to human gene therapy. There are proposals to remove the virulent genes from viruses to create vaccines. Plants have been engineered for scientific research, to create new colors in plants, deliver vaccines, and to create enhanced crops. Genetically modified crops are publicly the most controversial GMOs, in spite of having the most human health and environmental benefits. Animals are generally much harder to transform and the vast majority are still at the research stage. Mammals are the best model organisms for humans. Livestock is modified with the intention of improving economically important traits such as growth rate, quality of meat, milk composition, disease resistance, and survival. Genetically modified fish are used for scientific research, as pets, and as a food source. Genetic engineering has been proposed as a way to control mosquitos, a vector for many deadly diseases.
Benzodiazepines such as diazepam, alprazolam, clonazepam, and lorazepam, as well as alcohol, which act as GABAA receptor positive allosteric modulators, have been limitedly studied in combination with psilocybin and other psychedelics and are not known to directly interact with them. But these GABAergic drugs produce effects such as anxiolysis, sedation, and amnesia, and may therefore diminish or otherwise oppose psychedelics' effects. Because of this, recreational users often use benzodiazepines and alcohol as "trip killers" to manage difficult hallucinogenic experiences with psychedelics, such as experiences with prominent anxiety. This strategy's safety is not entirely clear and might have risks, but benzodiazepines have been used to manage psychedelics' adverse psychological effects in clinical studies and in emergency rooms. A clinical trial of psilocybin and midazolam coadministration found that midazolam clouded psilocybin's effects and impaired memory of the experience. Benzodiazepines might interfere with the therapeutic effects of psychedelics like psilocybin, such as sustained antidepressant effects. Psilocin, the active form of psilocybin, is a substrate of the monoamine oxidase (MAO) enzyme MAO-A. The exact extent to which psilocin (and by extension psilocybin) is metabolized by MAO-A is not fully clear, but has ranged from 4% to 33% in different studies based on metabolite excretion. Circulating levels of psilocin's deaminated metabolite are far higher than those of free unmetabolized psilocin with psilocybin administration.
Sucrose esters or sucrose fatty acid esters are a group of non-naturally occurring surfactants chemically synthesized from the esterification of sucrose and fatty acids (or glycerides). This group of substances is remarkable for the wide range of hydrophilic-lipophilic balance (HLB) that it covers. The polar sucrose moiety serves as a hydrophilic end of the molecule, while the long fatty acid chain serves as a lipophilic end of the molecule. Due to this amphipathic property, sucrose esters act as emulsifiers; i.e., they have the ability to bind both water and oil simultaneously. Depending on the HLB value, some can be used as water-in-oil emulsifiers, and some as oil-in-water emulsifiers. Sucrose esters are used in cosmetics, food preservatives, food additives, and other products. A class of sucrose esters with highly substituted hydroxyl groups, olestra, is also used as a fat replacer in food.
Sources: en.wikipedia.org
==== Fluorescent (nitrogen vacancy) ==== Fluorescent properties in nanodiamonds arise from the presence of nitrogen-vacancy (NV) centers, nitrogen atoms next to a vacancy. Fluorescent nanodiamond (FND) was invented in 2005 and has since been used in various fields of study. The invention received a US patent in 2008 States7326837 B2 United States 7326837 B2, Chau-Chung Han; Huan-Cheng Chang & Shen-Chung Lee et al., "Clinical applications of crystalline diamond particles", issued February 5, 2008, assigned to Academia Sinica, Taipei (TW) , and a subsequent patent in 2012 States8168413 B2 United States 8168413 B2, Huan-Cheng Chang; Wunshian Fann & Chau-Chung Han, "Luminescent Diamond Particles", issued May 1, 2012, assigned to Academia Sinica, Taipei (TW) . NV centers can be created by irradiating nanodiamonds with high-energy particles (electrons, protons, helium ions), followed by vacuum-annealing at 600–800 °C. Irradiation forms vacancies in the diamond structure while vacuum-annealing migrates these vacancies, which will get trapped by nitrogen atoms within the nanodiamond. This process produces two types of NV centers. Two types of NV centers are formed—neutral (NV0) and negatively charged (NV–)—and these have different emission spectra. The NV– the center is of particular interest because it has an S = 1 spin ground state that can be spin-polarized by optical pumping and manipulated using electron paramagnetic resonance.
In a few cases, autofluorescence may actually illuminate the structures of interest, or serve as a useful diagnostic indicator. For example, cellular autofluorescence can be used as an indicator of cytotoxicity without the need to add fluorescent markers. The autofluorescence of human skin can be used to measure the level of advanced glycation end-products (AGEs), which are present in higher quantities during several human diseases.
18 hours) in CYP2D6 poor metabolizers versus CYP2D6 extensive metabolizers. Circulating 4-hydroxyatomoxetine levels are about 1% of those of circulating atomoxetine levels in CYP2D6 extensive metabolizers and about 0.1% of those of circulating atomoxetine levels in CYP2D6 poor metabolizers. Similarly, N-desmethylatomoxetine circulates at much lower levels than atomoxetine, about 5% of those of atomoxetine in CYP2D6 extensive metabolizers and 45% of those of atomoxetine in CYP2D6 poor metabolizers. 4-Hydroxyatomoxetine shows similar affinity for the norepinephrine transporter (NET) as atomoxetine but much higher affinity for the serotonin transporter (SERT) in comparison (with SERT affinity ~14-fold lower than NET affinity), whereas N-desmethylatomoxetine shows much lower affinity for the monoamine transporters (MATs) than atomoxetine and 4-hydroxyatomoxetine (with NET affinity ~20-fold lower than that of atomoxetine). Despite differences in atomoxetine metabolism, CYP2D6 status has been said in literature reviews to not affect the overall tolerability and safety of atomoxetine. However, poor metabolizers did show greater heart rate increase (+9.4–11 bpm vs. +5.0–7.5 bpm), blood pressure increase (4.21 mm Hg vs. 2.13 mm Hg systolic and 2.75 mg Hg vs. 2.40 mm Hg diastolic), and more weight loss (–1.2 kg vs. +0.8 mg) than extensive metabolizers.
SR-BII (Scavenger Receptor Class B Type II): SR-BII, similar to SR-BI, is involved in lipid transfer and also binds AGEs. It plays a role in mediating the uptake of AGE-modified proteins and helps reduce cellular stress caused by AGEs. By participating in lipid metabolism and AGE clearance, SR-BII contributes to mitigating oxidative damage and supporting cellular homeostasis. DC-SIGN (Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Non-integrin): DC-SIGN is a receptor expressed on dendritic cells and is primarily involved in pathogen recognition and immune responses. Recent research suggests that DC-SIGN can also bind AGEs and mediate their clearance, which helps reduce AGE-induced immune activation. By modulating the immune response to AGEs, DC-SIGN plays a role in maintaining immune homeostasis and preventing chronic inflammation associated with AGE accumulation.
Sources: en.wikipedia.org
KFC is a subsidiary of Yum! Brands, one of the largest restaurant companies in the world. KFC had sales of $23 billion in 2013. KFC is incorporated under Delaware General Corporation Law, and has its headquarters at 1441 Gardiner Lane, Louisville, Kentucky, in a three-story colonial style building known colloquially as the "White House" due to its resemblance to the US president's home. The headquarters contain executive offices and the company's research and development facilities. In 2025, Yum! Brands plans to move the KFC headquarters to Plano, Texas.
=== Toxins interacting with proteins === Another non-food protein reaction, urushiol-induced contact dermatitis, originates after contact with poison ivy, eastern poison oak, western poison oak, or poison sumac. Urushiol, which is not itself a protein, acts as a hapten and chemically reacts with, binds to, and changes the shape of integral membrane proteins on exposed skin cells. The immune system does not recognize the affected cells as normal parts of the body, causing a T-cell-mediated immune response. Of these poisonous plants, sumac is the most virulent. The resulting dermatological response to the reaction between urushiol and membrane proteins includes redness, swelling, papules, vesicles, blisters, and streaking. Estimates vary on the fraction of the population that will have an immune system response. Approximately 25% of the population will have a strong allergic response to urushiol. In general, approximately 80–90% of adults will develop a rash if they are exposed to 0.0050 mg (7.7×10−5 gr) of purified urushiol. Some people are so sensitive that a molecular trace on the skin can initiate an allergic reaction.
Radon was discovered in 1899 by Ernest Rutherford and Robert B. Owens at McGill University in Montreal. It was the fifth radioactive element to be discovered, after uranium, thorium, radium, and polonium. In 1899, Pierre and Marie Curie observed that the gas emitted by radium remained radioactive for a month. Later that year, Rutherford and Owens noticed variations when trying to measure radiation from thorium oxide. Rutherford noticed that the compounds of thorium continuously emit a radioactive gas that remains radioactive for several minutes, and called this gas "emanation" (from Latin: emanare, to flow out, and emanatio, expiration), and later "thorium emanation" ("Th Em"). In 1900, Friedrich Ernst Dorn reported some experiments in which he noticed that radium compounds emanate a radioactive gas he named "radium emanation" ("Ra Em"). In 1901, Rutherford and Harriet Brooks demonstrated that the emanations are radioactive, but credited the Curies for the discovery of the element. In 1903, similar emanations were observed from actinium by André-Louis Debierne, and were called "actinium emanation" ("Ac Em"). Several shortened names were soon suggested for the three emanations: exradio, exthorio, and exactinio in 1904; radon (Ro), thoron (To), and akton or acton (Ao) in 1918; radeon, thoreon, and actineon in 1919, and eventually radon, thoron, and actinon in 1920.
== Function == LRP5 acts as a co-receptor with LRP6 and the Frizzled protein family members for transducing signals by Wnt proteins through the canonical Wnt pathway. This protein plays a key role in skeletal homeostasis.
The minister of agriculture, food sovereignty and forests is the head of the Republic of Italy's Ministry of Agriculture, Food Sovereignty and Forests. The ministry had been abolished by legislative referendum in 1993, during a period of great upheaval and financial sacrifices, but it was reconstituted in the same year until it assumed the current name in 2006. The current minister of the is Francesco Lollobrigida, of the Brothers of Italy party, who he is serving since 22 October 2022, in the government of Giorgia Meloni.
Sources: en.wikipedia.org
The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.
Cold storage at minus twenty degrees Celsius or below is the common recommendation for the lyophilized powder, together with protection from light and moisture. Dissolved material is generally treated as less stable and is handled cold with short working windows.
A useful certificate lists the analytical method used, the measured purity, the mass determined by spectrometry, and the storage conditions. Independent verification from a second laboratory is sometimes requested, since supplier-issued documents are not always produced in the same facility as the material.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.